QR-koodi

Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma

Dabrafenib plus trametinib is a promising new therapy for patients affected by BRAFV600E-mutant glioma, with high overall response and manageable toxicity. We described a complete and long-lasting response in a case of recurrent anaplastic pleomorphic xanthoastrocytoma CNS WHO-grade 3 BRAFV600E muta...

Täydet tiedot

Tallennettuna:
Päätekijät: Barbara Castelli, Marco Tellini, Melina Guidi, Marco Di Nicola, Laura Giunti, Anna Maria Buccoliero, Maria Luigia Censullo, Alessandro Iacono, Isacco Desideri, Lorenzo Genitori, Iacopo Sardi, Carla Fonte
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2024-05-01
Sarja:Frontiers in Oncology
Aiheet:
high-grade glioma
MEK inhibitors
target therapy
dabrafenib
trametinib
pleomorphic xanthoastrocytoma
Linkit:https://www.frontiersin.org/articles/10.3389/fonc.2024.1359093/full
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia